May 8, 2020
US biopharma Akebia Therapeutics' oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor vadadustat, which is under codevelopment with Otsuka Pharmaceutical outside Japan, met its primary endpoint in a multinational PIII program in patients on dialysis with anemia associated with chronic kidney...read more